Promises
3 promises
Promise Tracker
0 delivered, 0 close, 3 missed.
View Promises →
Fortis Healthcare Limited — Q4 FY25
Fortis Healthcare reported a strong Q4 FY25 with consolidated revenue of INR 2,007 crore (+12.5% YoY) and EBITDA margin of 21.7% (+40bps YoY).
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Fortis Healthcare reported a strong Q4 FY25 with consolidated revenue of INR 2,007 crore (+12.5% YoY) and EBITDA margin of 21.7% (+40bps YoY). Hospital revenue grew 14.2% to INR 1,701 crore, driven by 9% ARPOB growth and occupancy improvement to 69%. The diagnostic business (Agilus) saw margin expansion to 18% (gross basis) despite flattish revenue. Management guided for ~2% margin expansion in FY26 for hospitals, supported by brownfield bed additions (~1,000 beds) and operational efficiencies. Key risks include slower ramp-up of new beds (Manesar) and ongoing legal costs (~1% of EBITDA).
फोर्टिस हेल्थकेयर ने चौथी तिमाही में अच्छा प्रदर्शन किया। कंपनी की कुल कमाई 2,007 करोड़ रुपये रही, जो पिछले साल से 12.5% ज्यादा है। मुनाफा (EBITDA) 21.7% रहा। अस्पतालों की कमाई 14.2% बढ़कर 1,701 करोड़ रुपये हुई। मरीजों से प्रति बिस्तर कमाई 9% बढ़ी और 69% बिस्तर भरे रहे। डायग्नोस्टिक कारोबार (एगिलस) का मुनाफा 18% हो गया। कंपनी अगले साल अस्पतालों का मुनाफा 2% और बढ़ाने की योजना बना रही है। इसके लिए 1,000 नए बिस्तर जोड़े जाएंगे। लेकिन नए बिस्तरों (मानेसर) को भरने में देरी और कानूनी खर्च (मुनाफे का 1%) जोखिम हैं।
Promises0 met · 3 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Risks
4 risks
Risk Intelligence
Slower ramp-up of new beds impacting margins
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Hospital Occupancy
69%
+4pp YoY
Occupancy improved from 65% in FY24 to 69% in FY25, driven by volume growth and brownfield expansions.
ARPOB (Annual Revenue Per Occupied Bed)
INR 2.42 Cr
+9% YoY
ARPOB growth of 9% for FY25, driven by revenue gains in key specialties like oncology (+25%) and neurosciences (+19%).
International Patient Revenue Growth
17%
+17% YoY
International patient revenue grew 17% in Q4 to INR 145 crore, contributing 8.1% of hospital revenue.
Agilus EBITDA Margin (Gross)
18%
+400bps YoY
Agilus gross EBITDA margin improved to 18% in Q4 from 14% last year, driven by cost efficiencies and network rationalization.
What Changed vs Last Quarter
NEW
Hospital revenue growth of 14-15% in FY26
Management expects hospital revenue to grow 14-15% in FY26, with ARPOB growth of 5-6% and volume growth making up the balance.
NEW
Hospital EBITDA margin expansion of ~200bps in FY26
Management guided for ~200bps margin expansion in the hospital business for FY26, similar to the improvement seen in FY25.
NEW
Agilus double-digit revenue growth and 23% EBITDA margin in FY26
Management targets double-digit revenue growth for Agilus in FY26, with EBITDA margin (net) around 23%, moving towards 25% in a couple of years.
NEW
~1,000 bed additions in FY26
Management plans to add approximately 1,000 beds in FY26 through brownfield expansions at Noida, Faridabad, Manesar, FMRI, and BG Road.
DROPPED
Hospital margin guidance of 20.5% for FY25
Management expects hospital EBITDA margin to reach 20.5% for the full year FY25, with a medium-term target of 25%.
DROPPED
Diagnostics margin guidance of 21-22% for FY25
Agilus Diagnostics is expected to deliver adjusted EBITDA margin of 21-22% for FY25.
DROPPED
Manesar greenfield to break even by Q1 FY26
The Manesar facility, currently at INR 5 crore monthly revenue, is expected to break even at INR 9 crore per month by Q1 FY26.
DROPPED
Agilus to reach industry growth of 8-10% by Q2 FY26
Agilus expects to return to industry-level growth of 8-10% by Q2 FY26, driven by volume growth.
NEW RISK
Slower ramp-up of new beds impacting margins
The large bed addition plan (~1,000 beds) may face ramp-up delays, with Manesar already incurring an EBITDA loss of INR 12 crore in Q4.
NEW RISK
Legal and legacy costs persist
Legal and other legacy costs continue to consume ~1% of EBITDA, with no near-term resolution expected for the Delhi High Court case.
NEW RISK
Geopolitical risks to international patient revenue
International patient revenue growth of 17% may not sustain due to geopolitical tensions, though management expects stable contribution.
RISK GONE
Manesar ramp-up slower than expected
The greenfield facility posted an operating loss of INR 12-13 crore in Q3; any delay in reaching break-even could pressure margins.
RISK GONE
Legal costs and open offer uncertainty
Ongoing legal cases related to the open offer and forensic audit could result in elevated legal expenses and management distraction.
RISK GONE
Competitive intensity in hospital expansion
Aggressive bed additions by peers and potential talent wars could pressure occupancy and margins, though management downplays near-term impact.
🤫 Topics management stopped discussing
Mentioned in Q1 FY24, Q2 FY24, Q3 FY24
Brownfield bed expansion plan to add ~2,200 beds, with ~710 beds expected in FY25, including the Manesar acquisition.
Mentioned in Q1 FY25, Q3 FY25
Agilus expects to return to industry-level growth of 8-10% by Q2 FY26, driven by volume growth.
Mentioned in Q1 FY24, Q2 FY24
Management identified potential delays in brownfield bed commissioning as a key risk to achieving FY25 margin targets.
Mentioned in Q1 FY24, Q2 FY24
Rapid growth in medical oncology (lower margin) relative to surgical oncology could cap margin expansion despite absolute EBITDA growth.
Mentioned in Q3 FY24, Q3 FY25
The greenfield facility posted an operating loss of INR 12-13 crore in Q3; any delay in reaching break-even could pressure margins.
Fast read
Guidance and risk preview
Management expects hospital revenue to grow 14-15% in FY26, with ARPOB growth of 5-6% and volume growth making up the balance.
The large bed addition plan (~1,000 beds) may face ramp-up delays, with Manesar already incurring an EBITDA loss of INR 12 crore in Q4.
View Risks →